OverviewSuggest Edit

Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines for the treatment of eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. Its products include injections to treat macular edema, moderate-to-severe atopic dermatitis, heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, rheumatoid arthritis. The company also offers injections to treat cryopyrin-associated periodic syndromes and metastatic colorectal cancer. In addition, it develops a trap-based clinical product for the treatment of neovascular glaucoma, and antibody-based clinical programs.

TypePublic
Founded1988
HQTarrytown, NY, US
Websiteregeneron.com
Employee Ratings4.1
Overall CultureB-

Latest Updates

Employees (est.) (Dec 2021)10,368(+14%)
Job Openings888
Revenue (FY, 2021)$16.1 B(+90%)
Share Price (May 2022)$645.5(+2%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Regeneron Pharmaceuticals

Leonard S. Schleifer

Leonard S. Schleifer

Founder, President and Chief Executive Officer
Elizabeth Green

Elizabeth Green

Senior Director, Environment, Health & Safety
Daniel Van Plew

Daniel Van Plew

Executive Vice President and General Manager, Industrial Operations and Product Supply
George D. Yancopoulos

George D. Yancopoulos

Scientific Founder, President and Chief Scientific Officer
Nouhad Husseini

Nouhad Husseini

Senior Vice President, Business Development
Chris Fenimore

Chris Fenimore

Senior Vice President, Head of Accounting and Controller
Show more

Regeneron Pharmaceuticals Office Locations

Regeneron Pharmaceuticals has offices in Tarrytown, Bernards, Rensselaer, Sleepy Hollow and in 4 other locations
Tarrytown, NY, US (HQ)
777 Old Saw Mill River Rd
Bernards, NJ, US
110 Allen Rd, Basking Ridge
Rensselaer, NY, US
81 Columbia Turnpike
Sleepy Hollow, NY, US
1 Rockwood Rd
Washington, DC, US
1399 New York Ave NW
Dublin, IE
Harcourt St
Show all (8)

Regeneron Pharmaceuticals Financials and Metrics

Regeneron Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
Regeneron Pharmaceuticals's revenue was reported to be $16.07 b in FY, 2021
USD

Revenue (FY, 2021)

16.1b

Gross profit (FY, 2021)

13.6b

Gross profit margin (FY, 2021), %

84.8%

Net income (FY, 2021)

8.1b

EBIT (FY, 2021)

8.9b

Market capitalization (13-May-2022)

69.4b

Closing stock price (13-May-2022)

645.5

Cash (31-Dec-2021)

2.9b

EV

69.2b
Regeneron Pharmaceuticals's current market capitalization is $69.4 b.
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

6.7b7.9b8.5b16.1b

Revenue growth, %

14%17%8%

Cost of goods sold

434.1m782.2m1.1b2.4b

Gross profit

6.3b7.1b7.4b13.6b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

1.7b1.9b2.0b1.8b2.0b2.3b2.5b5.1b3.5b

Cost of goods sold

179.2m152.5m226.6m217.3m275.5m274.0m308.0m693.7m453.2m

Gross profit

1.5b1.8b1.8b1.6b1.7b2.0b2.2b4.4b3.0b

Gross profit Margin, %

90%92%89%88%86%88%88%86%87%
Annual
USDFY, 2019FY, 2020FY, 2021

Cash

1.6b2.2b2.9b

Accounts Receivable

2.7b3.1b6.0b

Prepaid Expenses

387.1m160.8m332.4m

Inventories

1.4b1.9b2.0b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

1.7b1.0b1.4b2.2b2.0b1.6b1.4b2.1b3.4b

Accounts Receivable

2.3b2.5b2.7b2.9b2.8b4.0b4.2b7.0b5.5b

Prepaid Expenses

182.2m208.2m226.9m226.6m263.8m230.6m213.6m444.3m482.0m

Inventories

1.2b1.3b1.3b1.5b1.6b1.8b2.2b2.0b2.1b
Annual
USDFY, 2019FY, 2020FY, 2021

Net Income

2.1b3.5b8.1b

Depreciation and Amortization

210.3m235.9m286.2m

Inventories

(335.5m)(529.4m)(494.3m)

Accounts Payable

444.5m118.9m866.1m
Quarterly
USDFY, 2018

Revenue/Employee

906.9k
Show all financial metrics

Regeneron Pharmaceuticals Operating Metrics

FY, 2018FY, 2019FY, 2020

Patents (US)

182131

Product Candidates

212232

Products

777

Trademarks

121318
Show all operating metrics

Regeneron Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
Eastside Campus Holdings LLC
Loop Road Holdings LLC
Old Saw Mill Holdings LLC
OSMR Holdings
Regeneron Assurance, Inc.
Regeneron Atlantic Holdings
Regeneron Belgium BV
Regeneron Canada Company
Regeneron Capital International B.V.
Regeneron Genetics Center LLC
Show more

Regeneron Pharmaceuticals Revenue Breakdown

Embed Graph

Regeneron Pharmaceuticals revenue breakdown by business segment: 65.5% from Product Sales, 27.9% from Sanofi and Bayer Collaboration and 6.6% from Other

Human Capital Metrics

Source: craft.co
Embed Graph
Show all human capital metrics

Regeneron Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

SecurityScorecard logo

Regeneron Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Regeneron Pharmaceuticals Online and Social Media Presence

Embed Graph

Regeneron Pharmaceuticals Company Culture

  • Overall Culture

    B-

    78/100

  • CEO Rating

    A

    84/100

  • Compensation

    A-

    85/100

Learn more on Comparably

Regeneron Pharmaceuticals News and Updates

Worldwide Antibody Cocktails Industry to 2028 - Featuring Cipla, Regeneron Pharmaceuticals and AstraZeneca Among Others

Dublin, April 04, 2022 (GLOBE NEWSWIRE) -- The "Antibody Cocktails Market, by Type, by Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering. An antibody, also called immunoglobul…

Worldwide Choroidal Neovascularization Industry to 2026 - Featuring Novartis, Pfizer and Regeneron Pharmaceuticals Among Others

Dublin, Sept. 30, 2021 (GLOBE NEWSWIRE) -- The "Choroidal Neovascularization Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global choroidal neovascularization market reached a value of US$ 5.…

Regeneron Pharmaceuticals (REGN) Long-Term Investor Alert: Contact Johnson Fistel Regarding Investigation

SAN DIEGO, July 30, 2021 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) against certain of its current and former officers and directors. 

Up 6% Last Week Can Regeneron Pharmaceuticals Stock Rise Further?

Over the past few months we have maintained our view that Regeneron stock looks undervalued. The stock has largely been in focus since last year amid the development of REGEN-COV, its Covid-19 antibody cocktail. While the treatment has already secured the U.S. FDA EUA (emergency use authorization)..

Regeneron Pharmaceuticals Earns Top Buy Rating For November

Just because a company has a good quarter in the past doesn’t mean that their stock prices will continue to rise in the future. That’s why our AI models provide an in-depth look at a company’s financials and performance so you can make the best decisions for your portfolio.

Kaskela Law LLC Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Long-Term REGN Stockholders to Contact the Firm

PHILADELPHIA, Sept. 5, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) on behalf of the Company's stockholders. On June 24, 2020, the U.S. Attorney's Office filed a complaint against...
Show more

Regeneron Pharmaceuticals Blogs

High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair

High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair william.meady@… Fri, 05/13/2022 - 11:53 High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International…

Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation Content Import Thu, 04/07/2022 - 01:00 Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Infl…

Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022

Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022 Content Import Tue, 04/05/2022 - 16:07 Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022 …

FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis

FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis Content Import Mon, 04/04/2022 - 01:00 FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis …

Students Win $1.8 Million at Regeneron Science Talent Search 2022 for Exceptional Research on Neutron Star--Black Hole Systems, Narrowband Radar, and Ribosome Movement in Protein Translation

Students Win $1.8 Million at Regeneron Science Talent Search 2022 for Exceptional Research on Neutron Star--Black Hole Systems, Narrowband Radar, and Ribosome Movement in Protein Translation Content Import Tue, 03/15/2022 - 21:19 Students Win $1.8 Million at Regeneron Science Talent Search…

Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

CAMBRIDGE, Mass. and TARRYTOWN, N.Y. , Feb. 28, 2022 /PRNewswire/ -- Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levels Durable serum TTR reductions observed with patient
Show more

Regeneron Pharmaceuticals Frequently Asked Questions

  • When was Regeneron Pharmaceuticals founded?

    Regeneron Pharmaceuticals was founded in 1988.

  • Who are Regeneron Pharmaceuticals key executives?

    Regeneron Pharmaceuticals's key executives are Leonard S. Schleifer, Elizabeth Green and Daniel Van Plew.

  • How many employees does Regeneron Pharmaceuticals have?

    Regeneron Pharmaceuticals has 10,368 employees.

  • What is Regeneron Pharmaceuticals revenue?

    Latest Regeneron Pharmaceuticals annual revenue is $16.1 b.

  • What is Regeneron Pharmaceuticals revenue per employee?

    Latest Regeneron Pharmaceuticals revenue per employee is $1.6 m.

  • Who are Regeneron Pharmaceuticals competitors?

    Competitors of Regeneron Pharmaceuticals include Intersect ENT, Catalent and Bristol-Myers Squibb.

  • Where is Regeneron Pharmaceuticals headquarters?

    Regeneron Pharmaceuticals headquarters is located at 777 Old Saw Mill River Rd, Tarrytown.

  • Where are Regeneron Pharmaceuticals offices?

    Regeneron Pharmaceuticals has offices in Tarrytown, Bernards, Rensselaer, Sleepy Hollow and in 4 other locations.

  • How many offices does Regeneron Pharmaceuticals have?

    Regeneron Pharmaceuticals has 8 offices.